Today, Cybin shared topline, interim data from a Phase 2 study of its deuterated DMT candidate (CYB003) in major depressive disorder (MDD). Below is our quick reaction to Cybin’s announcement, including comments from Cybin CEO, Doug Drysdale. Earlier today, psychedelic drug developer Cybin shared interim topline data from a study of its deuterated psilocybin candidate, CYB003…
